Skip to main content

Advertisement

Log in

“Vestibular migraine”: effects of prophylactic therapy with various drugs

A retrospective study

  • ORIGINAL COMMUNICATION
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Vertigo is frequently associated with migraine, and sometimes it is the cardinal symptom. This type of migraine is called “vestibular migraine”, “migrainous vertigo”, or “migraine-associated vertigo”. Earlier findings on effective prophylactic medication for such migraine attacks and their clinical features are few and insufficient. Our aim was to study the influence of prophylactic therapy on this type of migraine and to specify its clinical features. In a retrospective approach 100 patients (median age 47 years, range 21–72 years) with definite or probable vestibular migraine [1] were divided into two groups: those with (74 patients) and those without drug prophylaxis (26 patients). They were then interviewed by telephone at least 6 months after beginning therapy. All patients receiving medical prophylaxis showed a decrease of duration, intensity, and frequency of episodic vertigo as well as nearly all its associated features (p < 0.01). The group without medical prophylactic therapy showed only a reduction of vertigo intensity. Only 39 % of the 100 patients met the current IHS criteria for a basilartype migraine [2]. Thus, we propose that a new category – “vestibular migraine” – should be added to the HIS criteria. Furthermore, our data show that prophylactic medication may be effective for treating vestibular migraine and its associated symptoms; therefore, patient’s response to medical therapy may provide guidance in the diagnostic process of vestibular migraine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Neuhauser H, Leopold M, von Brevern M, Arnold G, Lempert T (2001) The interrelations of migraine, vertigo, and migrainous vertigo. Neurology 56:436–441

    PubMed  CAS  Google Scholar 

  2. 2. International Classification of Headache Disorders, 2nd edition (2004) Cephalalgia 24:9–160

    Google Scholar 

  3. Dieterich M, Brandt T (1999) Episodic vertigo related to migraine (90 cases): vestibular migraine? J Neurol 246:883–892

    Article  PubMed  CAS  Google Scholar 

  4. Brandt T (2004) A chameleon among the episodic vertigo syndromes: ‘migrainous vertigo’ or ‘vestibular migraine’. Cephalalgia 24:81–82

    Article  PubMed  CAS  Google Scholar 

  5. Brandt T, Strupp M (2006) Migraine and vertigo: classification, clinical features, and special treatment considerations. Headache Currents 3:12–19

    Article  Google Scholar 

  6. Neuhauser H, Lempert T (2004) Vertigo and dizziness related to migraine: a diagnostic challenge. Cephalalgia 24:83–91

    Article  PubMed  CAS  Google Scholar 

  7. Brantberg K, Trees N, Baloh RW (2005) Migraine-associated vertigo. Acta Otolaryngol 125:276–279

    Article  PubMed  Google Scholar 

  8. Stahl JS, Daroff RB (2001) Time for more attention to migrainous vertigo? Neurology 56:428–429

    PubMed  CAS  Google Scholar 

  9. Bikhazi P, Jackson C, Ruckenstein MJ (1997) Efficacy of antimigrainous therapy in the treatment of migraine-associated dizziness. Am J Otol 18:350–354

    PubMed  CAS  Google Scholar 

  10. Johnson GD (1998) Medical management of migraine-related dizziness and vertigo. Laryngoscope 108:1–28

    Article  PubMed  CAS  Google Scholar 

  11. Reploeg MD, Goebel JA (2002) Migraine- associated dizziness: patient characteristics and management options. Otol Neurotol 23:364–371

    Article  PubMed  Google Scholar 

  12. Bisdorff AR (2004) Treatment of migraine related vertigo with lamotrigine: an observational study. Bull Soc Sci Med Grand Duche Luxemb 2:103–108

    PubMed  Google Scholar 

  13. Carmona S, Settecase N (2005) Use of topiramate (topamax) in a subgroup of migraine-vertigo patients with auditory symptoms. Ann N Y Acad Sci 1039:517–520

    Article  PubMed  CAS  Google Scholar 

  14. Neuhauser HK, Radtke A, von Brevern M, Feldmann M, Lezius F, Ziese T, Lempert T (2006) Migrainous vertigo: prevalence and impact on quality of life. Neurology 67:1028–1033

    Article  PubMed  CAS  Google Scholar 

  15. Bank J, Marton S (2000) Hungarian migraine epidemiology. Headache 40:164–169

    Article  PubMed  CAS  Google Scholar 

  16. Ulrich V, Olesen J, Gervil M, Russell MB (2000) Possible risk factors and precipitants for migraine with aura in discordant twin-pairs: a populationbased study. Cephalalgia 20:821–825

    Article  PubMed  CAS  Google Scholar 

  17. Kayan A, Hood JD (1984) Neuro-otological manifestations of migraine. Brain 107:1123–1142

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to B. Baier M.D., Ph.D..

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baier, B., Winkenwerder, E. & Dieterich, M. “Vestibular migraine”: effects of prophylactic therapy with various drugs. J Neurol 256, 436–442 (2009). https://doi.org/10.1007/s00415-009-0111-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-009-0111-3

Key words

Navigation